

3. RELAPSED/REFRACTORY MULTIPLE MYELOMA

LONG-TERM PROGRESSION-FREE SURVIVAL BENEFIT WITH CILTACABTAGENE AUTOLEUCEL IN STANDARD-RISK RELAPSED/REFRACTORY MULTIPLE MYELOMA

D. Dytfield¹, L. J. Costa², A. Oriol³, S. Manier^{4,5}, P. M. Voorhees⁶, Y. Lin⁷, M. Htut⁸, W. Roeloffzen⁹, P. J. Ho^{10,11}, U. Shah^{12,13}, M. Zhao¹⁴, Q. Li¹⁵, A. Balogh¹⁶, K. Li¹⁷, A. Slaughter¹⁸, N. Benachour¹⁶, C. Lonardi¹⁹, A. Ghosh²⁰, H. Sun²⁰, N. Lendvai²⁰, T. Lengil²⁰, N. Patel²¹, M. Koneru²¹, E. Florendo²¹, O. Costa Filho²¹, V. Mahajan²¹, P. Rodríguez-Otero²², C. Strouse²³, A. K. Stewart^{24,25}, S. Sidana²⁶

¹Poznan University of Medical Sciences, Poznań, Poland; ²University of Alabama at Birmingham, USA; ³Hospital Germans Trias i Pujol, Barcelona, Spain; ⁴University of Lille, France; ⁵Centre Hospitalier Universitaire Lille, France; ⁶Wake Forest University, Charlotte, USA; ⁷Mayo Clinic, Rochester, USA; ⁸City of Hope Comprehensive Cancer Center, Duarte, USA; ⁹University Medical Center Groningen, The Netherlands; ¹⁰Royal Prince Alfred Hospital, Sydney, Australia; ¹¹The University of Sydney, Australia; ¹²Memorial Sloan Kettering Cancer Center, New York, USA; ¹³Weill Cornell Medical College, New York, USA; ¹⁴IQVIA, Shanghai, China; ^{15,16,17,18,19,20}Johnson & Johnson; ²¹Legend Biotech USA Inc, Somerset, USA; ²²Universidad de Navarra, Pamplona, Spain; ²³University of Iowa, Iowa City, USA; ²⁴University Health Network, Toronto, Canada; ²⁵The Princess Margaret Cancer Centre, Toronto, Canada; ²⁶Stanford University, USA

<https://doi.org/10.3324/haematol.2026.s2.14061>

Introduction. CARTITUDE-4 (NCT04181827) enrolled patients with lenalidomide-refractory multiple myeloma (MM) after 1-3 prior lines of therapy (pLOT) and showed a significant benefit of ciltacabtagene autoleucel (cilta-cel) over established triplet regimens. However, the benefit of cilta-cel for patients with standard-risk cytogenetics is less characterized. Here, outcomes in patients with standard-risk cytogenetics from CARTITUDE-4 are reported.

Methods. In CARTITUDE-4, patients randomized to cilta-cel underwent apheresis and bridging therapy (pomalidomide, bortezomib, and dexamethasone [PVD] or daratumumab, pomalidomide, and dexamethasone [DPd]), followed by lymphodepletion (cyclophosphamide and fludarabine), and a subsequent single cilta-cel infusion. A validated computerized algorithm was used to assess progression-free survival (PFS). The intent-to-treat (ITT) population included 208 patients; 32 progressed or died on bridging therapy and 176 were included in the as-treated population. Patients with high-risk cytogenetics (del(17p), t(14;16), t(4;14), gain/amp(1q); n=105), or with unknown cytogenetics (n=12), were not included in the as-treated analysis. Twelve-month minimal residual disease (MRD)-negative complete response (CR) was defined per the International Myeloma Working Group criteria. PFS rates were determined from the time of cilta-cel infusion for the as-treated population.

Results. In the ITT population of CARTITUDE-4, patients with standard-risk cytogenetics had a 30-month PFS rate (95% CI) of 71.0% (58.8-80.2) with cilta-cel (N=69) vs 43.2% (31.3-54.5) with standard of care (N=70) at a median

follow-up of 33.6 months. Participants with standard-risk cytogenetics in the as-treated population (n=59) had a 30-month PFS rate of 80.5% (95% CI, 67.2-88.8). In CARTITUDE-1 (NCT03548207), evaluating cilta-cel in patients with heavily pretreated relapsed/refractory MM (RRMM; ≥3 pLOT), the 30-month PFS rate among patients with standard-risk cytogenetics (negative for del(17p), t(14;16), or t(4;14); n=68) was 59.9% (95% CI, 47.2-70.5). The CARTITUDE-4 as-treated population with standard-risk cytogenetics experienced 8 PFS events within 1 year and 4 PFS events beyond 1 year of cilta-cel infusion. MRD-negative CR was achieved by 26 patients at 12 months after cilta-cel, 100.0% of whom were progression free at 30 months. Fourteen patients were not assessed for MRD because of calibration failure (n=12), no sample availability for testing (n=1), or indeterminate results post baseline (n=1).

Conclusions. The PFS rate at 2.5 years for participants with standard-risk RRMM was higher in CARTITUDE-4 compared with CARTITUDE-1, supporting the use of cilta-cel as early as second line. Among as-treated patients in CARTITUDE-4, 80.0% of those with standard-risk cytogenetics were progression free and off treatment at 2.5 years; this rate increased to 100.0% in patients with standard-risk disease who attained MRD-negative CR at 1 year. The low rate of progression events in cilta-cel-treated patients with standard-risk cytogenetics demonstrated the profound benefit of a single cilta-cel infusion in this population.

© American Society of Hematology (2025). Reused with permission.